Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Company Deals

Insilico Medicine and THPharma Launch AI Research Collaboration to Build ‘Reverse Translation’ Drug Discovery Strategy Around Phase 3 Candidate THP-001

Fineline Cube Aug 13, 2026
Company Deals

Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China

Fineline Cube Aug 13, 2026
Policy / Regulatory

NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026

Fineline Cube Aug 14, 2026
Company Drug

CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included

Fineline Cube Aug 14, 2026
Company Drug

Celgenyx Secures FDA IND Clearance for CG101 Off‑the‑Shelf iPSC‑Derived Cell Therapy in Acute Myeloid Leukemia – Multicenter Phase I Study to Begin

Fineline Cube Aug 14, 2026
Company Drug

Ocumension Therapeutics’ Zerviate Receives NMPA Priority Review for Ophthalmology Treatment

Fineline Cube Apr 27, 2023

Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that its histamine H1...

Company Deals

Dizal Pharma Plans to Raise $376.1 Million for Drug R&D and Industrialization

Fineline Cube Apr 27, 2023

Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192), the China-based joint venture established by AstraZeneca (AZ,...

Drug Policy / Regulatory

NMPA Mandates Label Updates for 11 Drug Varieties Including Black Box Warnings

Fineline Cube Apr 27, 2023

The National Medical Products Administration (NMPA) has released 10 notifications regarding revisions to package inserts...

Company Deals

Shanghai Fosun Pharmaceutical Reported to Halt Sale of Stake in Gland Pharma

Fineline Cube Apr 27, 2023

Indian media sources, including ET Now, have reported that Shanghai Fosun Pharmaceutical Group Co., Ltd...

Company Deals

LaNova Medicines and LegoChem Biosciences Partner to Develop Innovative ADC Product

Fineline Cube Apr 26, 2023

Shanghai-based cancer therapy developer LaNova Medicines Ltd has entered into a research partnership agreement with...

Company Deals

Sunshine Guojian Pharmaceutical and Shenyang 3SBio Secure Exclusive Licensing Agreement for Antitumor Programs

Fineline Cube Apr 26, 2023

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...

Company Drug

Junshi Biosciences Submits Market Filings for PCSK9 mAb Ongericimab to NMPA

Fineline Cube Apr 26, 2023

China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced the submission of two market filings...

Policy / Regulatory

Jiangsu Initiates Price Negotiations for Provincial Stock Drugs, Addresses Shortages

Fineline Cube Apr 26, 2023

The Jiangsu Public Resource Trading Platform has released a notification indicating the commencement of price...

Company Deals Digital

Ping An Healthcare and Technology Partners with Chugai Pharmaceutical to Establish Angina Pectoris Center

Fineline Cube Apr 26, 2023

Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also recognized as PingAn Good Doctor,...

Company Drug

Belief BioMed Completes Patient Dosing in Phase III Hemophilia B Gene Therapy Trial

Fineline Cube Apr 26, 2023

Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced the completion of patient dosing...

Company Deals

Tot Biopharmaceutical and Shanghai Escugen Partner on ADC Development and Commercialization

Fineline Cube Apr 26, 2023

China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Shanghai...

Company Drug

Zhaoke Ophthalmology’s US Partner Visus Therapeutics Reports Positive Phase III Results

Fineline Cube Apr 26, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), announced that its...

Company Deals

Meilitech Secures Series A+ Funding Led by Autobio Diagnostics for Cancer Detection Tech

Fineline Cube Apr 26, 2023

Shenzhen-based nanopore early cancer detection product developer, Meilitech Co., has reportedly raised tens of millions...

Company Deals

Sable Therapeutics and Liuqiang Medical Ink Licensing Deal for Aesthetic Fat Reduction Patch

Fineline Cube Apr 26, 2023

US-based Sable Therapeutics has announced plans to sign a licensing agreement with China-based Liuqiang Medical...

Company

Olympus Corp. to Invest $40.6 Million in New Endoscope Factory in Suzhou, China

Fineline Cube Apr 25, 2023

Japan-based optics giant Olympus Corp. is expanding its footprint in China with a planned investment...

Company Deals

Beijing-Based Holox Secures Tens of Millions in Series A+ Financing for Healthcare Software

Fineline Cube Apr 25, 2023

Holox, a Beijing-based developer of healthcare management software, has reportedly secured tens of millions of...

Company Deals

Shanghai Kingstar Winning Secures $43.39 Million in Series C Financing for Digital Healthcare Solutions

Fineline Cube Apr 25, 2023

Shanghai Kingstar Winning Software Science and Technology Co., Ltd, a leading provider of digitalization risk...

Company Deals

Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics

Fineline Cube Apr 25, 2023

Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is...

Company Drug

Gan & Lee Pharmaceuticals Receives Marketing Approval for Insulin Glargine in Bolivia

Fineline Cube Apr 25, 2023

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced that it has...

Company Medical Device

Rainmed Medical’s caIMR System Receives NMPA Approval for Coronary Artery Function Measurement

Fineline Cube Apr 25, 2023

China-based Rainmed Medical Limited has announced that it has received market approval from the National...

Posts pagination

1 … 574 575 576 … 708

Recent updates

  • CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included
  • ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions
  • Celgenyx Secures FDA IND Clearance for CG101 Off‑the‑Shelf iPSC‑Derived Cell Therapy in Acute Myeloid Leukemia – Multicenter Phase I Study to Begin
  • NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026
  • TJ Biopharma and Biogen Win NMPA Approval for Felzartamab (JINGFEI) in Multiple Myeloma – First Commercial Milestone Under Greater China Licensing Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included

Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Company Drug

Celgenyx Secures FDA IND Clearance for CG101 Off‑the‑Shelf iPSC‑Derived Cell Therapy in Acute Myeloid Leukemia – Multicenter Phase I Study to Begin

Policy / Regulatory

NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.